2021

RINVOQ (Upadacitinib) – Educational brochure for healthcare professionals

Educational brochure for healthcare professionals on safety information when prescribing upadacitinib: serious and opportunistic infections, herpes zoster, risks of birth defects, cardiovascular and venous thromboembolic complications. Contains recommendations on patient monitoring, reporting of adverse reactions, and working with the patient reminder card. compiled automatically

LEFLUTAB Information letter for healthcare professionals

Information letter for doctors on additional materials to the instructions for the medicinal product Leflutab: warnings regarding hepatotoxicity and hematotoxicity, teratogenicity, necessary laboratory tests and leflunomide elimination procedures. Intended for rheumatologists and healthcare professionals. compiled automatically

Notice of temporary supply shortage for the medicinal product ACTEMRA®

Notice for healthcare professionals about the expected temporary shortage of the medicinal product tocilizumab in Ukraine from October 2021, indicating the timelines for restoring supply and recommendations on managing the risk of disease exacerbation in patients and on alternative treatment options. generated automatically

“Questionnaire for healthcare professionals prescribing combined hormonal contraceptives to minimize the risks of the medicinal product Midiana

Questionnaire for healthcare professionals who prescribe combined hormonal contraceptives, aimed at minimizing the risks of thromboembolism. Contains questions for assessing contraindications and risk factors in a female patient before prescribing the product. generated automatically

Soliqua

Educational guide for healthcare professionals on the prescribing and use of a medicinal product based on insulin glargine with lixisenatide in two prefilled pens with different dosages. Contains instructions on dosing, differences between the devices, patient training, and prevention of errors. compiled automatically

Regarding the potential shortage of the medicinal product VINCRISTINE-TEVA

Letter-appeal to oncologists, hematologists, and chemotherapists about a potential shortage of vincristine solution for injection in Ukraine from September 2021 until at least the second quarter of 2022 due to disruptions in the supply of API, with a call to take this into account when prescribing treatment. compiled automatically

“Important information on minimizing the risk of aortic aneurysm and dissection and heart valve regurgitation/insufficiency with the use of levofloxacin

Regarding risk minimization when using the medicinal product Humira®

An information card for adult patients using the medicinal product Humira (adalimumab), with fields for entering data about the patient, the doctor and the injection, a section on the diagnosis and treatment of tuberculosis, a list of symptoms of possible adverse reactions and contacts for reporting them. compiled automatically

Tablets with a changed composition of excipients Euthyrox® (levothyroxine): monitoring of patients switching between tablets

Information letter for healthcare professionals on the transition of patients to Euthyrox tablets with a changed composition of excipients that do not contain lactose. Contains recommendations on monitoring the levothyroxine dose, risk groups, and reporting of adverse reactions. generated automatically

Lynparza. Risk of medication errors after approval of a new pharmaceutical form

Information letter for healthcare professionals about the risk of errors when using different dosage forms of olaparib (capsules and tablets), which are not interchangeable due to differences in dosing and bioavailability. Contains recommendations on proper prescribing, dispensing, and instructing of patients to prevent overdose or reduced efficacy. compiled automatically